Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Response to concerns over primate brain studies
monkeys
Scientists raised concerns about the level of suffering involved in many neuroscience experiments.
Scientists say experiments are crucial for fighting human disease
 
Over 400 scientists have signed a letter claiming that research on primates is crucial for tackling neurodegenerative and other crippling diseases such as Parkinson's.

The letter, published by the Guardian, follows recent calls to end support for primate brain studies that involve fluid deprivation and movement restraint.

A group of 21 experts including Dr Jane Goodall and Sir David Attenborough last week wrote an open letter to UK and EU bodies that are responsible for licensing and funding brain experiments on monkeys.

They raised concerns about the level of suffering involved in many neuroscience experiments, particularly those depriving animals of water and restraining their movement, and said there are now sufficient human-based alternatives to 'call into serious question whether further research of this type is necessary.'

But hundreds of scientists have responded by saying research on non-human primates has played a key part in life-changing medical advances - including treatments for leprosy, HIV and Parkinson's - and their 'careful and considered use' is necessary for the ongoing fight against crippling human diseases.

'The biological similarities between humans and other primates mean that they are sometimes the only effective model for complex neurodegenerative diseases such as Parkinson's,' they wrote.

The group acknowledged that such research requires greater ethical justification due to the intelligence and sensitivity of non-human primates, and said the scientific community works together to minimise suffering 'wherever possible'.

They added: 'Stringent regulations across the developed world exist to ensure that primates are only used where there is no other available model – be that the use of a mouse or a non-animal alternative – and to protect the wellbeing of those animals still required. The use of primates is not undertaken lightly.'

However Dr Jane Goodall, who has studied chimpanzees for over 50 years, believes it is "morally wrong" to confine our primate relatives to laboratory cages and subject them to experiments that are often painful and distressing. In addition, she said fluid deprivation and movement restraint is "inhumane and extremely cruel".

 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.